What is Seer?
Founded in 2017 and headquartered in Redwood City, California, Seer operates at the intersection of biotechnology and data science. The company specializes in capturing high-resolution molecular data from the proteome, a field that remains one of the most complex and untapped frontiers in modern medicine. By developing innovative platforms that enable researchers to observe biology at an unprecedented scale, Seer is effectively bridging the gap between genomic potential and clinical reality. Their market position is defined by a commitment to enabling breakthroughs in understanding disease mechanisms, which has attracted significant interest from institutional investors focused on long-term healthcare innovation and high-growth life science ventures.
How much funding has Seer raised?
Seer has raised a total of $479.5M across 7 funding rounds:
Series A
$6M
Series B
$36M
Series C
$17.5M
Series D
$55M
Multiple Rounds
$365M
Series A (2017): $6M with participation from Maverick Ventures
Series B (2018): $36M led by Invus and Maverick Ventures
Series C (2019): $17.5M supported by Invus, Maverick Ventures, AJU IB INVESTMENT, and Wing Companies
Series D (2019): $55M featuring aMoon
Other Financing Round (2020): $55M backed by Maverick Ventures, HBM Healthcare Investments AG, T. Rowe Price Associates, Fidelity Investments Inc., Invus, and aMoon
Share Placement (2020): $135M with participation from aMoon Fund, T. Rowe Price, Fidelity, and SoftBank
Stock Issuance/Offering (2020): $175M led by Undisclosed
Key Investors in Seer
Maverick Ventures
Maverick Ventures Israel is a venture capital firm dedicated to supporting technology start-ups by providing investment and operational support, with a focus on AI, healthcare, and cybersecurity.
HBM Healthcare Investments AG
HBM Healthcare Investments is a publicly traded investment company focused on the global healthcare sector, aiming to capitalize on growth opportunities driven by medical advancements.
T. Rowe Price Associates
Founded in 1937, T.Rowe Price Group provides comprehensive investment management services to institutional investors and retirement plans, managing equity and fixed income funds globally.
What's next for Seer?
Following its recent major strategic investment, Seer is well-positioned to accelerate the commercialization of its proteomic platforms and expand its footprint within the global research community. The company's strategic roadmap likely involves scaling its operational capacity to meet the increasing demand for deep molecular profiling in both academic and pharmaceutical settings. As Seer continues to refine its technology, the focus will shift toward establishing broader partnerships and integrating its insights into clinical workflows. This phase of growth is critical for transitioning from a research-focused entity to a foundational provider of diagnostic and therapeutic intelligence, ensuring that the company remains at the forefront of the precision medicine revolution.
See full Seer company page
